RG 6047

Drug Profile

RG 6047

Alternative Names: ARN 927; GDC-0927; RG-6047; SERD 2; SRN-927

Latest Information Update: 10 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aragon Pharmaceuticals
  • Developer Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Preclinical Endometrial cancer; Ovarian cancer

Most Recent Events

  • 01 Mar 2015 Phase-I clinical trials in Breast cancer (Hormone refractory, Late-stage disease, Metastatic disease) in USA (PO)
  • 04 Dec 2014 Genentech and Seragon Pharmaceuticals plan a phase I trial for Breast cancer (Hormone refractory, Late-stage disease) in USA (NCT02316509)
  • 27 Aug 2014 Seragon Pharmaceuticals has been acquired by Genentech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top